Search

•Effective donor lymphocyte infusion (DLI) after transplantation does not require graft-versus-host disease.•Competitive stem cell repopulation can suffice for full donor engraftment.•Donor anti-patient immune reactivity promotes full donor T cell chimerism.•DLI promotes conversion to full donor lymphohematopoiesis.

Imatinib trough levels have been associated with its clinical effects. During chronic use of imatinib, CYP2C8 becomes an important metabolizing enzyme because of cytochrome P450 3A4 (CYP3A4) autoinhibition. Single nucleotide polymorphisms (SNPs) in CYP2C8may affect imatinib trough levels. This study investigates the effect of common CYP2C8polymorphisms [*1B(rs7909236), *1C(rs17110453), *3(rs11572080 and rs10509681), and *4(rs1058930)] on steady-state trough levels imatinib during chronic imatinib use in 43 patients with chronic myeloid leukemia or gastrointestinal stromal tumors. Standardized imatinib trough levels did not show a significant difference between wild-type and variant groups for any of the tested SNPs, but an association with age was found, with older patients having higher trough levels. This suggests that common CYP2C8SNPs have no effect on the pharmacokinetics of imatinib.